logo

For the Inventor, By the Inventor

Tokyo, Japan

Shoji Omoto

This inventor holds 10 USPTO granted patents. Top assignees: Meiji Seika Kaisha, Ltd., Meiji Seika Co., Ltd.. Active years: 1976-1982.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shoji Omoto. Retrieved from https://idiyas.com/inventor/shoji-omoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 100.0

Average Co-Inventor Count = 6.2

ph-index = 4

Forward Citations = 38(Granted Patents)


Location History:

  • Tokyo, JA (1976 - 1977)
  • Tokyo, JP (1979 - 1982)

Company Filing History:

goldMedal9 out of 382 
 
Meiji Seika Kaisha, Ltd.
 patents
silverMedal1 out of 3 
 
Meiji Seika Co., Ltd.
 patents

Years Active: 1976-1982

Loading Chart...
10 patents (USPTO):Explore Patents
1. 4316894 - Antibiotic SF-1130-x.sub.3 3 substance and production and use thereof (1982-02-23),
2. 4302580 - Process for the production of a cephamycin derivative (1981-11-24),
3. 4242327 - Antibiotic SF-2052 substance and production and use thereof (1980-12-30),
4. 4169140 - Antibiotics SF-1771 substance and SF-1771-B substance as well as the (1979-09-25),
5. 4160026 - Antibiotics SF-1130-x.sub.1 and -x.sub.2 substances and production and (1979-07-03),
6. 4151041 - Process for production of maltopentaose and maltohexaose (1979-04-24),
7. 4029881 - Antibiotic 9-acyl-3'-thiomethoxymethyl-SF-837 composition and process (1977-06-14),
8. 4017607 - 9,3',4'-Triacyl ester of the antibiotic SF-837 M.sub.1 substance and the (1977-04-12),
9. 3959256 - 9-O-Alkanoyl-3'-O-alkanoyloxymethyl-SF-837 substance and the production (1976-05-25),
10. 3940479 - Novel antibiotic BN-109 substance, its production and use (1976-02-24),

Title: Shoji Omoto: A Pioneer in Antibiotic Innovation

Introduction

Shoji Omoto, a notable inventor based in Tokyo, Japan, has made significant contributions to the field of pharmaceuticals through his groundbreaking inventions, particularly in the development of antibiotics. With a portfolio that boasts ten patents, Omoto has displayed an exceptional talent for innovation in the pharmaceutical sector.

Latest Patents

Among his latest patents is the creation of Antibiotic SF-1130-x.sub.3. This innovative substance is produced by cultivating a microorganism, Streptomyces myxogenes SF-1130, under aerobic conditions. The antibiotic is extracted from the fermentation broth and serves as an effective inhibitor of α-glucosidase and saccharase. Furthermore, when administered orally, it effectively suppresses blood sugar elevation in living animals after starch and sugar intake. Another notable patent involves a new process for producing a cephamycin derivative, a chemotherapeutic and antibacterial agent. This process starts economically and efficiently from cephamycin A and/or B and entails several key steps including reaction, protection through acylation and esterification, and the condensation of D-cysteine.

Career Highlights

Shoji Omoto has been associated with prominent companies including Meiji Seika Kaisha, Ltd. and Meiji Seika Co., Ltd. His work in these organizations has been pivotal in advancing antibiotic research and development.

Collaborations

Throughout his career, Omoto has collaborated with esteemed colleagues such as Taro Niida and Takashi Shomura. These partnerships have enriched his work and led to remarkable advancements in pharmaceutical innovation.

Conclusion

Shoji Omoto's contributions to antibiotic research and his inventive spirit highlight him as a leading figure in the field. His patents not only mark significant advancements in medicine but also demonstrate the essential role of innovation in addressing health challenges. As his work continues to evolve, the impact of his inventions is likely to resonate within the medical community for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…